Joseph H. Wender Sells 10,000 Shares of Ionis Pharmaceuticals Inc (IONS) Stock

Share on StockTwits

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Joseph H. Wender sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $79.63, for a total transaction of $796,300.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

IONS opened at $80.50 on Friday. The company has a current ratio of 7.88, a quick ratio of 7.85 and a debt-to-equity ratio of 0.53. The firm has a market cap of $11.10 billion, a price-to-earnings ratio of 34.42 and a beta of 2.40. Ionis Pharmaceuticals Inc has a 1 year low of $39.07 and a 1 year high of $81.03.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, February 27th. The company reported $2.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.01 by $2.20. The firm had revenue of $192.00 million for the quarter, compared to the consensus estimate of $159.59 million. Ionis Pharmaceuticals had a net margin of 45.64% and a return on equity of 41.89%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.03) EPS. On average, analysts expect that Ionis Pharmaceuticals Inc will post -0.1 EPS for the current fiscal year.

A number of analysts have commented on the stock. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. JPMorgan Chase & Co. boosted their price target on shares of Ionis Pharmaceuticals from $47.00 to $55.00 and gave the company a “neutral” rating in a research note on Monday. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 15th. TheStreet upgraded shares of Ionis Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, March 1st. Finally, Morgan Stanley set a $71.00 price target on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $59.88.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC boosted its holdings in Ionis Pharmaceuticals by 8.7% during the 3rd quarter. FMR LLC now owns 20,463,839 shares of the company’s stock worth $1,055,525,000 after acquiring an additional 1,635,782 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Ionis Pharmaceuticals by 1.4% during the 3rd quarter. Vanguard Group Inc. now owns 11,091,298 shares of the company’s stock worth $572,089,000 after acquiring an additional 157,770 shares during the last quarter. Vanguard Group Inc boosted its holdings in Ionis Pharmaceuticals by 1.4% during the 3rd quarter. Vanguard Group Inc now owns 11,091,298 shares of the company’s stock worth $572,089,000 after acquiring an additional 157,770 shares during the last quarter. BB Biotech AG boosted its holdings in Ionis Pharmaceuticals by 0.9% during the 4th quarter. BB Biotech AG now owns 8,741,334 shares of the company’s stock worth $472,557,000 after acquiring an additional 75,000 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in Ionis Pharmaceuticals by 2.9% during the 4th quarter. BlackRock Inc. now owns 7,676,257 shares of the company’s stock worth $414,977,000 after acquiring an additional 213,000 shares during the last quarter. 84.31% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4239841/joseph-h-wender-sells-10000-shares-of-ionis-pharmaceuticals-inc-ions-stock.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Read More: What are economic reports?

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

First Republic Bank  Shares Sold by Hahn Capital Management LLC
First Republic Bank Shares Sold by Hahn Capital Management LLC
MetLife Investment Advisors LLC Has $60.42 Million Position in Mastercard Inc
MetLife Investment Advisors LLC Has $60.42 Million Position in Mastercard Inc
Northfield Bancorp Inc  EVP Robin Lefkowitz Sells 769 Shares
Northfield Bancorp Inc EVP Robin Lefkowitz Sells 769 Shares
Einsteinium Price Tops $0.12 on Major Exchanges
Einsteinium Price Tops $0.12 on Major Exchanges
Dixon Hubard Feinour & Brown Inc. VA Purchases 182 Shares of Boeing Co
Dixon Hubard Feinour & Brown Inc. VA Purchases 182 Shares of Boeing Co
Republic Bancorp, Inc. KY  Given Consensus Rating of “Hold” by Brokerages
Republic Bancorp, Inc. KY Given Consensus Rating of “Hold” by Brokerages


© 2006-2019 Ticker Report